Skip to main content

Advertisement

SpringerLink
Log in

Initial Experience with Genomic Profiling of Heavily Pretreated Breast Cancers

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Rapidly evolving advances in the understanding of theorized unique driver mutations within individual patient’s cancers, as well as dramatic reduction in the cost of genomic profiling, have stimulated major interest in the role of such testing in routine clinical practice. The aim of this study was to report our initial experience with genomic testing in heavily pretreated breast cancer patients.

Methods

Patients with primary or recurrent breast cancer managed at any of our five hospitals and whose malignancy had failed to respond to therapy or had progressed on all recognized standard-of-care options were offered the opportunity to have their cancer undergo next-generation sequencing genomic profiling.

Results

Of a total of 101 patients, 98 (97 %) had at least one specific genomic alteration identified. A total of 465 different somatic genetic abnormalities were revealed in this group of patients. Although 52 % of patients were found to have an abnormality for which an U.S. Food and Drug Administration (FDA)-approved drug was available, 69 % of patients had an FDA-approved agent for an indication other than breast cancer. The most common genomic alterations of potential clinical consequence were PIK3 (25 %), FGFR1 (16 %), AKT (11 %), PTEN (10 %), ERBB2 (8 %), JAK2 (6 %), and RAF1 (5 %).

Conclusions

Almost all advanced breast cancers possess at least one well-characterized genomic alteration that might be actionable at the clinical level. Further, in most cases, a plausible argument can be advanced for the potential biological and clinical relevance of an FDA-approved antineoplastic agent not currently indicated in the treatment of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  2. Sabatier R, Goncalves A, Bertucci F. Personalized medicine: present and future of breast cancer management. Crit Rev Oncol Hematol. 2014;pii:S1040-8428(14)00051-1.

  3. Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012:743193.

    PubMed  PubMed Central  Google Scholar 

  4. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.

    Article  PubMed  CAS  Google Scholar 

  5. Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38:698–707.

    Article  PubMed  CAS  Google Scholar 

  6. Giordano A, Tagliabue E, Pupa SM. Promise and failure of targeted therapy in breast cancer. Front Biosci (Schol Ed). 2012;4:356–74.

    Article  PubMed  Google Scholar 

  7. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–52.

    PubMed  CAS  PubMed Central  Google Scholar 

  8. Ma CX, Ellis MJ. The Cancer Genome Atlas: clinical applications for breast cancer. Oncology (Williston Park). 2013;27:1263–9.

    Google Scholar 

  9. Cizkova M, Dujaric ME, Lehmann-Che J, et al. Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer. 2013;108:1807–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395–402.

    Article  PubMed  CAS  Google Scholar 

  11. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117–27.

    Article  PubMed  CAS  Google Scholar 

  12. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008;68:8022–30.

    Article  PubMed  CAS  Google Scholar 

  13. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.

    Article  PubMed  CAS  Google Scholar 

  14. Kean S. Breast cancer. The “other” breast cancer genes. Science. 2014;343(6178):1457–9.

    Article  PubMed  Google Scholar 

  15. Ellsworth RE, Decewicz DJ, Shriver CD, Ellsworth DL. Breast cancer in the personal genomics era. Curr Genomics. 2010;11:146–61.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Balko JM, Giltnane JM, Wang K, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4:232–45.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014;20:1757–67.

    Article  PubMed  CAS  Google Scholar 

  18. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;65:2554–9.

    Article  PubMed  CAS  Google Scholar 

  19. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084–91.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Quintas-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013;19:1933–40.

    Article  PubMed  CAS  Google Scholar 

  21. Zhao W, Du Y, Ho WT, Fu X, Zhao ZJ. JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines. Exp Hematol Oncol. 2012;1:15.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  22. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 2011;10:1093–101.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Lee SY, Haq F, Kim D, et al. Comparative genomic analysis of primary and synchronous metastatic colorectal cancers. PLoS One. 2014;9:e90459.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20:1953–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28:4877–83.

    Article  Google Scholar 

Download references

Acknowledgment

Supported in part by Cancer Treatment Centers of America®.

Disclosure

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Cancer Treatment Centers of America® (CTCA), Goodyear, AZ, USA

    Edgar D. Staren MD, PhD, Donald Braun PhD, Bradford Tan MD, Digant Gupta MD, MPH, Kim Kramer SSGB & Maurie Markman MD

  2. The Translational Genomics Research Institute (TGen), Phoenix, AZ, USA

    Edgar D. Staren MD, PhD & Seungchan Kim PhD

Authors
  1. Edgar D. Staren MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald Braun PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bradford Tan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Digant Gupta MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seungchan Kim PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kim Kramer SSGB
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maurie Markman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Digant Gupta MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Staren, E.D., Braun, D., Tan, B. et al. Initial Experience with Genomic Profiling of Heavily Pretreated Breast Cancers. Ann Surg Oncol 21, 3216–3222 (2014). https://doi.org/10.1245/s10434-014-3925-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-3925-x

Keywords

Search

Navigation